- Press Release Distribution

Human organ chips enable COVID-19 drug repurposing

Emulating the human lung airway in vitro identified the SARS-CoV2-inhibiting effects of the antimalarial drug amodiaquine, which is now in COVID-19 clinical trials

( A Wyss Institute-led collaboration spanning four research labs and hundreds of miles has used the Institute's organ-on-a-chip (Organ Chip) technology to identify the antimalarial drug amodiaquine as a potent inhibitor of infection with SARS-CoV-2, the virus that causes COVID-19.

The Organ Chip-based drug testing ecosystem established by the collaboration greatly streamlines the process of evaluating the safety and efficacy of existing drugs for new medical applications, and provides a proof-of-concept for the use of Organ Chips to rapidly repurpose existing drugs for new medical applications, including future pandemics. The research is reported in Nature Biomedical Engineering.

While many groups around the world have been testing existing drugs for efficacy against COVID-19 using cultured cells, it is well known that cells grown in a dish do not behave like the cells in a living human body, and many drugs that appear effective in lab studies do not work in patients. The Wyss team examined eight existing drugs, including hydroxychloroquine and chloroquine, that they and others had found were active against SARS-CoV-2 in conventional cell culture assays.

When tested in their more sophisticated microfluidic Lung Airway Chip, which had been infected with a pseudotyped SARS-CoV-2 virus, they found that most of these drugs, including hydroxychloroquine and chloroquine, were not effective. However, another antimalarial drug, amodiaquine, was highly effective at preventing viral entry. These results were then validated in cultured cells and in a small animal model of COVID-19 using infectious SARS-CoV-2 virus. Amodiaquine is now in clinical trials for COVID-19 at multiple sites in Africa, where this drug is inexpensive and widely available.

"The speed with which this team assembled, pivoted to COVID-19, and produced clinically significant results is astonishing," said senior author and Wyss Institute Founding Director Don Ingber, M.D., Ph.D. "We started testing these compounds in February 2020, had data by March, and published a preprint in April. Thanks to the openness and collaboration that the pandemic has sparked within the scientific community, our lead drug is now being tested in humans. It's a powerful testament to Organ Chips' ability to accelerate preclinical testing."

From mysterious disease to lead compound in months In the early months of the COVID-19 pandemic when little was known about the novel SARS-CoV-2 virus, efforts were made around the globe to identify existing drugs that could be repurposed to treat patients who were falling ill. While early data performed on cells grown in lab dishes seemed to suggest that the antimalarial drugs chloroquine and hydroxychloroquine could treat the disease, later studies showed that they aren't active against SARS-CoV-2 in animals or patients, and the quest for an effective oral therapeutic that can both treat and prevent COVID-19 continues.

Fortunately, the Wyss Institute had a ready-made solution to that problem. In a move that today seems prescient, over three years ago the Defense Advanced Research Projects Agency (DARPA) and National Institutes of Health (NIH) awarded funding to Ingber's team to explore whether its human Organ Chip microfluidic culture technology, which faithfully mimics the function of human organs in vitro, could be used to confront potential biothreat challenges including pandemic respiratory viruses.

Two years into the project, the team was making steady progress using its lung Airway Chip to study drugs that could be repurposed to treat influenza virus infections. Then, in January 2020, first authors Longlong Si, Ph.D. and Haiqing Bai, Ph.D. heard about cases of what was being called a novel viral pneumonia in China.

"That caught a lot of scientists' attention, because any new virus could become a global threat given how easily infections spread in today's era of widespread international travel. We closely followed the updates because we thought that our Airway Chip model could provide an important tool for studying this virus," said Si, a Wyss Technology Development Fellow and co-lead author. Once it became clear that people were falling ill due to the mysterious COVID-19 and not pneumonia, the team quickly shifted its focus to the novel SARS-CoV-2 virus.

The human Airway Chip that the Wyss team developed for these studies is a microfluidic device about the size of a USB memory stick that contains two parallel channels separated by a porous membrane. Human lung airway cells are grown in one channel that is perfused with air, while human blood vessel cells are grown in the other channel, which is perfused with liquid culture medium to mimic blood flow. Cells grown in this device naturally differentiate into multiple airway-specific cell types in proportions that are similar to those in the human airway, and develop traits observed in living lungs such as cilia and the ability to produce and move mucus. Airway Chip cells also have higher levels of angiotensin-converting enzyme-2 (ACE2) receptor protein, which plays a central role in lung physiology and is used by SARS-CoV-2 to infect cells.

"Our biggest challenge in shifting our focus to SARS-CoV-2 was that we don't have lab facilities with the necessary infrastructure to safely study dangerous pathogens. To get around that problem, we designed a SARS-CoV-2 pseudovirus that expresses the SARS-CoV-2 spike protein, so that we could identify drugs that interfere with the spike protein's ability to bind to human lung cells' ACE2 receptors," said Bai, who is a Postdoctoral Fellow at the Wyss Institute and co-lead author. "A secondary goal was to demonstrate that these types of studies could be carried out by other Organ Chip researchers who similarly have this technology, but lack access to lab facilities required to study highly infectious viruses."

Armed with the pseudovirus that allowed them to study SARS-CoV-2 infection, the team first perfused the Airway Chips' blood vessel channel with several approved drugs, including amodiaquine, toremifene, clomiphene, chloroquine, hydroxychloroquine, arbidol, verapamil, and amiodarone, all of which have exhibited activity against other related viruses in previous studies. However, in contrast to static culture studies, they were able to perfuse the drug through the channels of the chip using a clinically relevant dose to mimic how the drug would be distributed to tissues in our bodies. After 24 hours they introduced SARS-CoV-2 pseudovirus into the Airway Chips' air channel to mimic infection by airborne viruses, like that in a cough or sneeze.

Only three of these drugs ? amodiaquine, toremifene, and clomiphene ? significantly prevented viral entry without producing cell damage in the Airway Chips. The most potent drug, amodiaquine, reduced infection by about 60%. The team also performed spectrometry measurements with the assistance of Steve Gygi, Ph.D.'s group at Harvard Medical School to assess how the drugs impacted the airway cells. These studies revealed that amodiaquine produced distinct and broader protein changes than the other antimalarial drugs.

The researchers had a lead drug candidate.

All hands on deck Despite the promise of amodiaquine, the team still needed to demonstrate that it worked against the real infectious SARS-CoV-2 virus. With the help of a new COVID-19-focused grant from DARPA, Ingber teamed up with Matthew Frieman, Ph.D. at the University of Maryland School of Medicin and Benjamin tenOever, Ph.D. at the Icahn School of Medicine at Mount Sinai, both of whom already had biosafety labs set up to study infectious pathogens.

This collaboration created a drug discovery ecosystem that combines the human emulation capability of the Wyss Institute's Organ Chips with Frieman's and tenOever's expertise in the interactions between viruses and their host cells. The Frieman lab tested amodiaquine and its active metabolite, desethylamodiaquine, against native SARS-CoV-2 via high-throughput assays in cells in vitro, and confirmed that the drug inhibited viral infection.

In parallel, the tenOever lab tested amodiaquine and hydroxychloroquine against native SARS-CoV-2 in a head-to-head comparison in a small animal COVID-19 model, and saw that prophylactic treatment with amodiaquine resulted in ~70% reduction in viral load upon exposure, while hydroxychloroquine was ineffective. They also saw that amodiaquine prevented the transmission of the virus from sick to healthy animals more than 90% of the time, and that it was also effective in reducing viral load when administered after introduction of the virus. Thus, their results suggest that amodiaquine could work in both treatment and prevention modes.

"Seeing how beautifully amodiaquine inhibited infection in the Airway Chip was extremely exciting," said Frieman. "And, the fact that it seems to work both before and after exposure to SARS-CoV-2 means that it could potentially be effective in a wide variety of settings."

"This collaboration has allowed us to do things that we never would have had the resources to do otherwise, including recently setting up Organ Chips in our own lab so that we can now use them to study the interactions between infectious viruses and their hosts. While we're proud of what we've accomplished so far for COVID-19, we're also looking forward to studying additional virus-host dynamics using the Organ Chips in the hopes that we'll be able to prevent or address future pandemics," said tenOever, who is a Professor of Microbiology.

A preprint of the amodiaquine results was published online on April 15, 2020, which generated buzz in the scientific community. It eventually caught the eye of Medicines for Malaria Venture, a leading product development partnership in antimalarial drug research. These results, along with studies from several other groups, contributed to amodiaquine's inclusion in a clinical trial in collaboration with the University of Witwatersrand in South Africa and Shin Poong Pharmaceutical in South Korea last fall. A few months later, the Drugs for Neglected Diseases Initiative (DNDi) added amodiaquine to the ANTICOV clinical trial for COVID-19, which spans 19 sites in over 13 different countries in Africa. Amodiaquine is oral, extremely inexpensive, and widely available in Africa. If proven effective in these clinical trials, it could provide a badly needed weapon against COVID-19 in low-resource nations where access to vaccines and expensive new therapeutics is limited.

Preparing for the next pandemic While the identification of amodiaquine is a major boon in fighting COVID-19, the team already has their sights set on future pandemics. In addition to SARS-CoV-2, their recent publication details their success in finding drugs that could protect against or treat several strains of influenza virus.

"Thanks to our experience using this drug development pipeline to validate amodiaquine for COVID-19, we are now applying what we learned to influenza and other pandemic-causing pathogens," said co-author Ken Carlson, Ph.D., a Lead Senior Staff Scientist who helps lead the Coronavirus Therapeutic Project Team at the Wyss Institute. "This process has given us confidence that Organ Chips are predictive of what we see in more complex living models of viral infections, and helped harness the creative cauldron of the Wyss Institute to consolidate and strengthen our therapeutic discovery engine."

In addition to influenza, the team is now exploring drugs that could be used against the new SARS-CoV-2 mutant strains, to suppress the dangerous "cytokine storm" that leads to many hospitalizations, and to relieve the symptoms of COVID-19 "long haulers."

"The pandemic has really gelled the Wyss Institute's Bioinspired Therapeutics development program, and linking up with the Frieman and tenOever labs has created a drug discovery and development pipeline that dramatically speeds up the whole process, quickly shepherding COVID-19 drugs through preclinical development to the point where they can be tested in humans. With Organ Chip technology in hand, we are now in a stronger position to confront future pandemics," said Ingber, who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children's Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.


Additional authors of the paper include Melissa Rodas, Wuji Cao, Crystal Oh, Mercy Soong, Atiq Nurani, Seong Min Kim, Danni Zhu, Girija Goyal, Rani Powers, and Roberto Plebiani from the Wyss Institute; former Wyss Institute members Rachelle Prantil-Baun, Kambez Benam, and Sarah Gilpin; Amanda Jiang from Boston Children's Hospital and Harvard Medical School; Rasmus Moller, Daisy Hoagland, Kohei Oishi, Shu Horiuchi, Skyler Uhl, Daniel Blanco-Melo, Tristan Jordan, Benjamin Nilsson-Payant, Ilona Golynker, and Justin Frere from the Icahn School of Medicine at Mount Sinai; James Logue, Robert Haupt, Marisa McGrath, and Stuart Weston from the University of Maryland School of Medicine; Tian Zhang and Steve Gygi from Harvard Medical School;

This research was supported by the NIH (NCATS 1-UG3-HL-141797-01 and NCATS 1-UH3-HL- 141797-01), DARPA (W911NF-12-2-0036 and W911NF-16-C-0050), the Bill and Melinda Gates Foundation, the Marc Haas Foundation, and the Wyss Institute for Biologically Inspired Engineering at Harvard University.


Earthquake, tsunami hazards from subduction zones might be higher than current estimates

Earthquake, tsunami hazards from subduction zones might be higher than current estimates
Two of the most destructive forces of nature - earthquakes and tsunamis - might actually be more of a threat than current estimates according to new research conducted by scientists at The University of New Mexico and the Nanyang Technological University published today in Nature Geoscience. The researchers developed a new method to assess earthquake and tsunami hazards represented by the most distant part of offshore subduction zones and found that the hazard might have been systematically underestimated in some areas, meaning that tsunami risk assessments should be redone given the ...

GM grass cleanses soil of toxic pollutants left by military explosives, new study shows

GM grass cleanses soil of toxic pollutants left by military explosives, new study shows
A grass commonly used to fight soil erosion has been genetically modified to successfully remove toxic chemicals left in the ground from munitions that are dangerous to human health, new research shows. The study - led by the University of York- demonstrates that genetically modified switchgrass (Panicum virgatum) can detoxify residues of the military explosive, RDX, left behind on live-fire training ranges, munitions dumps and minefields. RDX has been a major component of munitions since WW2 which are still used extensively on military training grounds. This use has now resulted in widespread pollution of groundwater. Researchers generated the plants by inserting two genes from bacteria able to breakdown RDX. The plants were then grown in RDX contaminated ...

Researchers wirelessly record human brain activity during normal life activities

Researchers wirelessly record human brain activity during normal life activities
Researchers are now able to wirelessly record the directly measured brain activity of patients living with Parkinson's disease and to then use that information to adjust the stimulation delivered by an implanted device. Direct recording of deep and surface brain activity offers a unique look into the underlying causes of many brain disorders; however, technological challenges up to this point have limited direct human brain recordings to relatively short periods of time in controlled clinical settings. This project, published in the journal Nature Biotechnology, was funded by the National Institutes of Health's ...

CityU scientists invent cryomicroneedles for intradermal therapeutic cell delivery

A research team led by City University of Hong Kong (CityU) scientists recently developed a new generation of microneedles technology which allows the intradermal delivery of living cells in a minimally invasive manner. Their experiment showed that vaccination using therapeutic cells through this ground-breaking technology elicited robust immune responses against tumours in mice, paving the way for developing an easy-to-use cell therapy and other therapeutics against cancers and other diseases. The study was led by Dr Xu Chenjie, Associate Professor at the Department of Biomedical Engineering (BME) at CityU. The latest findings have been published in the scientific journal Nature Biomedical Engineering, titled "Cryomicroneedles for Transdermal Cell Delivery". The new technology ...

Scientists find small molecule cocktail to improve stem cell use in research, medicine

Researchers at the National Institutes of Health (NIH) have devised a four-part small-molecule cocktail that can protect stem cells called induced pluripotent stem cells (iPSCs) from stress and maintain normal stem cell structure and function. The researchers suggest that the cocktail could enhance the potential therapeutic uses of stem cells, ranging from treating diseases and conditions -- such as diabetes, Parkinson's disease and spinal cord injury -- to genome editing. Human pluripotent stem cells are cells that, in theory, can grow forever and serve as an inexhaustible source for specialized cells, such as brain, kidney and heart cells. But stem cells are sensitive, and their potential uses in ...

Mini 3D brain models could speed up search for MS treatments

Tiny 3-D models that mimic vital aspects of the human nervous system have been developed in a step that could accelerate drug research for neurological conditions such as multiple sclerosis (MS). The millimetre-wide models - created using stem cells from human skin samples - will be used to study myelin, an insulating substance that helps nerve cells communicate with each other. Researchers say the models are the most natural representation of human myelination developed in a lab and are a promising platform for studying neurological diseases and for testing drugs for conditions linked to myelin loss, including MS. Nerve cells are found in the brain and the spinal cord and connect to each other with ...

COVID-19 conspiracy beliefs increased among users of conservative and social media

PHILADELPHIA - Belief in conspiracies about the COVID-19 pandemic increased through the early months of the U.S. outbreak among people who reported being heavy users of conservative and social media, a study by Annenberg Public Policy Center (APPC) researchers has found. ...

Stress and mental health problems during first COVID-19-lockdown

Many people in Switzerland experienced considerable psychological distress during the first COVID-19 lockdown from mid-March to the end of April 2020. Researchers from the Department of Child and Adolescent Psychiatry and Psychotherapy at the University Hospital of Psychiatry Zurich (PUK) and the University of Zurich in collaboration with the La Source School of Nursing have now examined the most common sources of stress among children, adolescents, their parents and young adults. For their study, the researchers used representative samples in Switzerland of 1,627 young adults aged 19 to 24 as well as 1,146 children and adolescents between the ages of 12 and 17 and their parents. Uncertainty, disruption, postponement "Uncertainty during last year's lockdown was considerable ...

Flatfish got weird fast due to evolutionary cascade

Flatfish got weird fast due to evolutionary cascade
HOUSTON - (May 3, 2021) - Ever look at a flatfish like a flounder or sole, with two eyes on one side of its head, and think, "How did that happen?" You're in luck. Rice University biologist Kory Evans has the answer. "Flatfishes are some of the weirdest vertebrates on the planet, and they got weird very, very fast by changing multiple traits at once over a short period of time," said Evans, an assistant professor of biosciences at Rice who specializes in studying the evolution of fish over long time scales. Of all mammals, reptiles, birds, amphibians and fish, flatfish are easily the most asymmetric. Evans, the corresponding author ...

Equipping crop plants for climate change

Biologists at Ludwig-Maximilians-Universitaet (LMU in Munich) have significantly enhanced the tolerance of blue-green algae to high light levels - with the aid of artificial evolution in the laboratory.  Sunlight, air and water are all that cyanobacteria (more commonly known as blue-green algae), true algae and plants need for the production of organic (i.e. carbon-based) compounds and molecular oxygen by means of photosynthesis. Photosynthesis is the major source of building blocks for organisms on Earth. However, too much sunlight reduces the efficiency of photosynthesis because it damages the 'solar panels', i.e. the photosynthetic machineries of cyanobacteria, algae and plants. A team of researchers led by LMU biologist Dario Leister has ...


Worldwide network develops SARS-CoV-2 protocols for research laboratories

Sharks in protected area attract illegal fishers

Molecular tweezers that attack antibiotic resistant bacteria developed by Ben-Gurion U.

Cricket bats should be made from bamboo not willow, Cambridge study finds

Future-proofing mental health -- Experts set out research roadmap to prioritise key areas

Body mass index during childhood linked with risk of anorexia nervosa and bulimia nervosa in later life

Combining BMI with body shape better predictor of cancer risk, suggests

Higher BMI, body fat, and larger waist and hips pose similar risk for

Higher BMI in childhood may help protect women against breast cancer in later life, both before and after the menopause

Research shows for the first time that protein complexes 'inflammasomes' are linked to obesity-related colon cancer

New Strep A human challenge model paves the way to test vaccines against the deadly bacteria

How proteins control information processing in the brain

Study supports recommendations to avoid pregnancy for at least 12 months after obesity surgery

Most comprehensive studies to date find 'insufficient evidence' to support herbal and dietary supplements for weight loss

Vegetarians have healthier levels of disease markers than meat-eaters

Switch of breast tumors to HER2-low in recurrence may provide greater therapeutic options

Mild COVID-19 infection is very unlikely to cause lasting heart damage

Ice core data show why, despite lower sulfur emissions in US and Western Europe, air pollution is dropping more slowly

The Lancet Rheumatology: Largest study to date confirms non-steroidal anti-inflammatory medications do not result in worse COVID-19 outcomes

The legume family tree

New research sets stage for development of salmonella vaccine

New study examines social network's relation to binge drinking among adults

Archaeologists pinpoint population for the Greater Angkor region

Stop the genetic presses!

Sleep disorders tally $94.9 billion in health care costs each year

Turning a pancreatic cancer cell's addiction into a death sentence

How viruses and bacteria can reach drinking water wells

Latest peer-reviewed research: Immediate global ivermectin use will end COVID-19 pandemic

The structure of DNA is found to be actively involved in genome regulation

New innovation successfully treats neonatal hypothermia

[] Human organ chips enable COVID-19 drug repurposing
Emulating the human lung airway in vitro identified the SARS-CoV2-inhibiting effects of the antimalarial drug amodiaquine, which is now in COVID-19 clinical trials